ArticleEuropean journal of nuclear medicine and molecular imaging2016
Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Diagnostic Value of [Molecular imaging and biology · 2025Article
- Detection and quantification of small and low-uptake lesions for differentiated thyroid carcinoma using non-time-of-flight iodine-124 PET/MRI.Medical physics · 2025Article
- The Role of Positron Emission Tomography/Computed Tomography in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- Intra-Individual Comparison ofCancers · 2022Article
- Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer.Cancers · 2022Article
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.International journal of molecular sciences · 2022Review
- Head-to-Head Comparison of NeckCancers · 2021Article
- Value ofCancer management and research · 2021Article
- Comparison of simultaneousEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Thyroid cancer diagnosis in the era of precision imaging.Journal of thoracic disease · 2020Review
- Hybrid PET/MRI in major cancers: a scoping review.European journal of nuclear medicine and molecular imaging · 2019Article
- Quantitative performance ofEJNMMI physics · 2018Article
- Topics of nuclear medicine research in Europe.Annals of nuclear medicine · 2017Review
- Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Article
- PET and MRI: Is the Whole Greater than the Sum of Its Parts?Cancer research · 2016Article
- Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany.Molecular imaging and biology · 2016Article
- Imaging of differentiated thyroid carcinoma: (124)I-PET/MRI may not be superior to (124)I-PET/CT.European journal of nuclear medicine and molecular imaging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to compare integrated PET/CT and PET/MRI for their usefulness in detecting and categorizing cervical iodine-positive lesions in patients with differentiated thyroid cancer using (124)I as tracer.
methodsThe study group comprised 65 patients at high risk of iodine-positive metastasis who underwent PET/CT (low-dose CT scan, PET acquisition time 2 min; PET/CT2) followed by PET/MRI of the neck 24 h after (124)I administration. PET images from both modalities were analysed for the numbers of tracer-positive lesions. Two different acquisition times were used for the comparisons, one matching the PET/CT2 acquisition time (2 min, PET/MRI2) and the other covering the whole MRI scan time (30 min, PET/MRI30). Iodine-positive lesions were categorized as metastasis, thyroid remnant or inconclusive according to their location on the PET/CT images. Morphological information provided by MRI was considered for evaluation of lesions on PET/MRI and for volume information.
resultsPET/MRI2 detected significantly more iodine-positive metastases and thyroid remnants than PET/CT2 (72 vs. 60, p = 0.002, and 100 vs. 80, p = 0.001, respectively), but the numbers of patients with at least one tumour lesion identified were not significantly different (21/65 vs. 17/65 patients). PET/MRI30 tended to detect more PET-positive metastases than PET/MRI2 (88 vs. 72), but the difference was not significant (p = 0.07). Of 21 lesions classified as inconclusive on PET/CT, 5 were assigned to metastasis or thyroid remnant when evaluated by PET/MRI. Volume information was available in 34 % of iodine-positive metastases and 2 % of thyroid remnants on PET/MRI.
conclusionsPET/MRI of the neck was found to be superior to PET/CT in detecting iodine-positive lesions. This was attributed to the higher sensitivity of the PET component, Although helpful in some cases, we found no substantial advantage of PET/MRI over PET/CT in categorizing iodine-positive lesions as either metastasis or thyroid remnant. Volume information provided by MRI for some iodine-positive lesions might be useful in dosimetry.
Indexed as
Identifiers
26686334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.